EE04617B1 - 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena - Google Patents

2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena

Info

Publication number
EE04617B1
EE04617B1 EEP200000113A EEP200000113A EE04617B1 EE 04617 B1 EE04617 B1 EE 04617B1 EE P200000113 A EEP200000113 A EE P200000113A EE P200000113 A EEP200000113 A EE P200000113A EE 04617 B1 EE04617 B1 EE 04617B1
Authority
EE
Estonia
Prior art keywords
diarylpyrazolo
cox
inhibitors
preparation
pyridazine derivatives
Prior art date
Application number
EEP200000113A
Other languages
English (en)
Estonian (et)
Inventor
John Beswick Paul
Baxter Campbell Ian
Mathews Neil
Naylor Alan
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9718792.6A external-priority patent/GB9718792D0/en
Priority claimed from GBGB9727116.7A external-priority patent/GB9727116D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000113A publication Critical patent/EE200000113A/xx
Publication of EE04617B1 publication Critical patent/EE04617B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
EEP200000113A 1997-09-05 1998-09-03 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena EE04617B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9718792.6A GB9718792D0 (en) 1997-09-05 1997-09-05 Chemical compounds
GBGB9727116.7A GB9727116D0 (en) 1997-12-23 1997-12-23 Chemical compounds
PCT/EP1998/005558 WO1999012930A1 (fr) 1997-09-05 1998-09-03 Derives de 2,3-diaryl-pyrazolo[1,5-b]pyridazine, leur preparation et leur utilisation en tant qu'inhibiteurs de cyclooxygenase 2 (cox-2)

Publications (2)

Publication Number Publication Date
EE200000113A EE200000113A (et) 2000-12-15
EE04617B1 true EE04617B1 (et) 2006-04-17

Family

ID=26312181

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000113A EE04617B1 (et) 1997-09-05 1998-09-03 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena

Country Status (28)

Country Link
US (4) US6451794B1 (fr)
EP (3) EP1032575B1 (fr)
KR (1) KR100382619B1 (fr)
CN (1) CN1155600C (fr)
AP (1) AP1354A (fr)
AT (3) ATE281458T1 (fr)
AU (1) AU744997B2 (fr)
BG (1) BG64420B1 (fr)
BR (1) BR9812046A (fr)
CA (1) CA2303152A1 (fr)
DE (3) DE69827419T2 (fr)
DK (1) DK1032575T3 (fr)
EA (1) EA002775B1 (fr)
EE (1) EE04617B1 (fr)
ES (3) ES2231757T3 (fr)
HR (1) HRP20000122B1 (fr)
HU (1) HUP0003644A3 (fr)
IL (1) IL134688A (fr)
IS (1) IS5389A (fr)
NO (1) NO315559B1 (fr)
NZ (1) NZ502985A (fr)
PL (1) PL194557B1 (fr)
PT (1) PT1032575E (fr)
SK (1) SK283922B6 (fr)
TR (1) TR200000595T2 (fr)
TW (1) TW570922B (fr)
WO (1) WO1999012930A1 (fr)
YU (1) YU11900A (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231757T3 (es) * 1997-09-05 2005-05-16 Glaxo Group Limited Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina.
JP3420751B2 (ja) * 1998-11-03 2003-06-30 グラクソ グループ リミテッド 選択的ｃｏｘ‐２インヒビターとしてのピラゾロピリジン誘導体
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
GB9929039D0 (en) * 1999-12-08 2000-02-02 Glaxo Group Ltd Medicaments
GB9930358D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
WO2001045703A1 (fr) 1999-12-23 2001-06-28 Nitromed, Inc. Inhibiteurs de cyclooxygenase-2 nitroses et nitrosyles, compositions et procedes d'utilisation
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
PT1303265E (pt) 2000-07-20 2007-10-09 Lauras As ''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida''
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
GB0025449D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
US7153855B2 (en) 2001-03-08 2006-12-26 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
WO2002083672A1 (fr) 2001-04-10 2002-10-24 Smithkline Beecham Corporation Composes de pyrazolopyridine antiviraux
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
ES2242028T3 (es) 2001-04-27 2005-11-01 Smithkline Beecham Corporation Derivados de pirazolo(1,5-a)piridina.
GB0112802D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
CN1518550A (zh) 2001-06-21 2004-08-04 ʷ��˿�������ȳ�ķ���޹�˾ 用于预防和治疗疱疹病毒感染的咪唑并[1,2-a]吡啶衍生物
JP2005508955A (ja) 2001-10-05 2005-04-07 スミスクライン ビーチャム コーポレーション ヘルペスウイルス感染の治療で使用されるためのイミダゾ−ピリジン誘導体
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003050120A1 (fr) 2001-12-11 2003-06-19 Smithkline Beecham Corporation Derives de la pyrazolo-pyridine, agents anti-herpes
AU2002357164A1 (en) * 2001-12-17 2003-06-30 Smithkline Beecham Corporation Pyrazolopyridazine derivatives
KR100686537B1 (ko) 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
KR100840907B1 (ko) * 2001-12-28 2008-06-24 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난바이피리디닐 유도체
EP1474395B1 (fr) * 2002-02-12 2007-10-17 Smithkline Beecham Corporation Derives de nicotinamide utiles comme inhibiteurs de p38
GB0206200D0 (en) * 2002-03-15 2002-05-01 Glaxo Group Ltd Pharmaceutical compositions
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
ATE325115T1 (de) * 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
JP2006504728A (ja) 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0227443D0 (en) * 2002-11-25 2002-12-31 Glaxo Group Ltd Pyrimidine derivatives
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
ES2214130B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 2-3'-bipiridinas.
ES2213485B1 (es) * 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EP1534305B9 (fr) 2003-05-07 2007-03-07 Osteologix A/S Sels de strontium hydrosolubles pour le traitement d'affections de cartilage et/ou d'os
WO2005009342A2 (fr) * 2003-07-16 2005-02-03 Pharmacia Corporation Methode de traitement ou de prevention de troubles dermatologiques a l'aide d'un seul inhibiteur de la cyclooxygenase-2 ou en combinaison avec un agent de traitement dermatologique, et compositions contenant ceux-ci
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0319037D0 (en) * 2003-08-13 2003-09-17 Glaxo Group Ltd 7-Azaindole Derivatives
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (fr) * 2003-09-03 2005-03-17 Pharmacia Corporation Procede de prevention ou de traitement de la douleur, de l'inflammation, et de troubles lies a l'inflammation avec un inhibiteur selectif de cox-2 en combinaison avec un agent donneur de monoxyde d'azote et compositions en contenant
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
WO2006066968A1 (fr) 2004-12-23 2006-06-29 Glaxo Group Limited Composes de pyridine destines au traitement de maladies a mediation par prostaglandine
WO2006071274A2 (fr) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
WO2009042854A1 (fr) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Compositions régulatrices de canaux ioniques et procédés d'utilisation de ces dernières
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
WO2011012622A1 (fr) 2009-07-30 2011-02-03 Glaxo Group Limited Dérivés de benzoxazinone pour traiter des troubles induits par glytl
WO2011023753A1 (fr) 2009-08-27 2011-03-03 Glaxo Group Limited Dérivés de benzoxazine inhibiteurs du transport de glycine
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
JP5815029B2 (ja) 2010-07-09 2015-11-17 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネル遮断薬としてのテトラゾール化合物
JP6058556B2 (ja) 2011-01-19 2017-01-11 クオンベルゲンセ プハルマセウトイカルス リミテッド ＣａＶ２．２カルシウムチャンネルブロッカーとしてのピペラジン誘導体
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
CA3209491A1 (fr) 2021-03-15 2022-09-22 Saul Yedgar Dipalmitoyl-phosphatidyl-ethanol-amine conjuguee a l'acide hyaluronique en combinaison avec des medicaments anti-inflammatoires non steroidiens (ains) pour traiter ou soulager des maladies inflammatoire
CN115611901B (zh) * 2021-07-16 2024-04-30 华南理工大学 一种氮杂䓬类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4925849A (en) 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5155114A (en) 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
KR920702621A (ko) 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
JPH05508153A (ja) 1990-06-12 1993-11-18 スミスクライン・ビーチャム・コーポレイション ５―リポキシゲナーゼ経路およびシクロオキシゲナーゼ経路で媒介される疾患の阻害
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
AU1269495A (en) 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CN1186492A (zh) * 1995-04-04 1998-07-01 葛兰素集团有限公司 咪唑并[1,2－α]吡啶衍生物
US6136839A (en) 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
WO1996041645A1 (fr) * 1995-06-12 1996-12-27 G.D. Searle & Co. Traitement d'inflammations par une combinaison d'un inhibiteur de la cyclooxygenase-2 et d'un antagoniste du recepteur de leukotriene b¿4?
GB9513508D0 (en) * 1995-07-03 1995-09-06 Fujisawa Pharmaceutical Co Quinazoline derivatives
ES2231757T3 (es) * 1997-09-05 2005-05-16 Glaxo Group Limited Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina.
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2001515901A (ja) 2001-09-25
BR9812046A (pt) 2000-09-26
BG64420B1 (bg) 2005-01-31
US6861429B2 (en) 2005-03-01
EP1032575A1 (fr) 2000-09-06
ES2231757T3 (es) 2005-05-16
AU744997B2 (en) 2002-03-07
TR200000595T2 (tr) 2000-12-21
CN1155600C (zh) 2004-06-30
HRP20000122A2 (en) 2001-02-28
DE69827419T2 (de) 2005-10-27
ATE317845T1 (de) 2006-03-15
KR100382619B1 (ko) 2003-05-09
TW570922B (en) 2004-01-11
PL339059A1 (en) 2000-12-04
SK283922B6 (sk) 2004-05-04
CN1278263A (zh) 2000-12-27
CA2303152A1 (fr) 1999-03-18
US6831097B2 (en) 2004-12-14
NO20001102L (no) 2000-05-03
DE69827419D1 (de) 2004-12-09
IS5389A (is) 2000-02-25
EP1510519A1 (fr) 2005-03-02
WO1999012930A1 (fr) 1999-03-18
EP1369421A1 (fr) 2003-12-10
IL134688A (en) 2005-05-17
ES2203985T3 (es) 2004-04-16
ES2256817T3 (es) 2006-07-16
ATE281458T1 (de) 2004-11-15
US20030008872A1 (en) 2003-01-09
EA002775B1 (ru) 2002-08-29
DE69833464D1 (de) 2006-04-20
DE69816651D1 (de) 2003-08-28
US20030040517A1 (en) 2003-02-27
NZ502985A (en) 2002-04-26
KR20010023669A (ko) 2001-03-26
DE69816651T2 (de) 2004-04-01
AU9439598A (en) 1999-03-29
PT1032575E (pt) 2003-11-28
YU11900A (sh) 2002-11-15
HUP0003644A2 (hu) 2001-09-28
US20050113377A1 (en) 2005-05-26
IL134688A0 (en) 2001-04-30
EE200000113A (et) 2000-12-15
HRP20000122B1 (en) 2003-06-30
AP1354A (en) 2004-12-29
NO20001102D0 (no) 2000-03-03
NO315559B1 (no) 2003-09-22
EP1369421B1 (fr) 2004-11-03
PL194557B1 (pl) 2007-06-29
EP1510519B1 (fr) 2006-02-15
DE69833464T2 (de) 2006-08-24
EP1032575B1 (fr) 2003-07-23
US6451794B1 (en) 2002-09-17
BG104279A (en) 2000-12-29
HUP0003644A3 (en) 2002-11-28
JP3167700B2 (fr) 2001-05-21
EA200000188A1 (ru) 2000-10-30
DK1032575T3 (da) 2003-10-20
AP2000001753A0 (en) 2000-03-31
ATE245649T1 (de) 2003-08-15
SK2942000A3 (en) 2001-03-12

Similar Documents

Publication Publication Date Title
EE04617B1 (et) 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena
EE200200080A (et) Imidaso[1,2a]püridiini ja pürasolo[2,3a]püridiiniderivaadid
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
EE03765B1 (et) Propioonhappe derivaadid ja nende kasutamine
EE200000037A (et) Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
AU4777097A (en) Novel piperidineketocarboxylic acid derivatives, their preparation and use
FI990134A (fi) Pyridatsino-(4,5-beta)-kinoliini-5-oksidijohdannaisia, niiden valmistus ja niiden käyttö glysiiniantagonisteina
BR9711724A (pt) Derivado de 3,4,5,6,7,8-hexaidro-pirido (4',3':4,5)tieno-(2,3-d) pirimidina 3-substitu¡da e uso do mesmo
EE03830B1 (et) 1H-pürido[3,4-b]indool-4-karboksamiidi derivaadid, nende valmistamismeetodid ja kasutamine raviks
EE200000056A (et) 4-okso-3,5-dihüdro-4H-püridasino[4.5-b]indool-1-etaanamiidi derivaadid, nende valmistamine ja kasutamine raviks
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE200000207A (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, nende valmistamine ja terapeutiline kasutamine
AU6120298A (en) 2-peperazinone-1-acetic acid derivatives and their use
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
EE9800085A (et) 3,5-difluoropüridiinid, nende valmistamismeetod, herbitsiidne kompositsioon ja nende kasutamine
SI1032575T1 (en) 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
AU3134199A (en) Antimicrobial betaGalNAc(1-4)betaGal derivatives and methods of use
AU5522499A (en) 2-aminoethyl-quinoline derivatives, preparation and therapeutic use
AU1476900A (en) 1,4,5,6-tetrahydro-pyridazine derivatives, their preparation and their use as neuraminidase inhibitors
FI950021A (fi) Tienopyrimidiinijohdannaiset, niiden valmistus ja käyttö
SI0977741T1 (en) Substituted phenyl derivatives, their preparation and use

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20080903